No

Antilipemic Agent (Miscellaneous)

Reduction of elevated serum cholesterol

C

Euthyroid patients with one of the following: Organic heart disease (including ischemic); congestive heart failure, advanced renal or hepatic disease, history of myocardial infarction, cardiac arrhythmias, rheumatic heart disease, hypertension, history of ischism

Use with caution in patients with a history of angina pectoris, severe hypertension, or myocardial infarction, Do not use for treatment of obesity due to risk of life-threatening toxicity. Discontinue 2 weeks prior to elective surgery. Increased serum thyroxine levels are to be expected; do not interpret as hypermetabolism.

<1% (Limited to important or life-threatening symptoms): Myocardial infarction, angina, arrhythmias, insomnia, headache, alopecia, rash, weight loss, tremor, paresthesia, visual disturbances, tinnitus, diaphoresis

Warfarin's effects are increased; avoid concurrent use or decrease warfarin's dose and monitor INR closely.

Cholestyramine decreases the absorption of dextrothyroxine; separate administration.

TCAs may increase nervousness, CNS stimulation, tachycardia, and other arrhythmias.

Beta-blockers may decrease the pharmacologic effects of dextrothyroxine.

Digoxin's efficacy may be reduced with exacerbation of arrhythmias or heart failure.

Antidiabetic agents may need dose increased to combat hyperglycemia caused by dextrothyroxine.

Unclear mechanism, thought to increase the liver breakdown of cholesterol

Absorption: Poorly absorbed from GI tract (25%)

Serum half-life: 18 hours

Oral:

Adults: 1-2 mg/day, increase at 1-2 mg at intervals of 4 weeks, up to a maximum of 8 mg/day

Low-fat, low-cholesterol may be recommended

There is no clear benefit for the use of dextrothyroxine in the management of hyperlipidemia

May cause insomnia

Concurrent use with TCAs may increase their toxicity

No information available to require special precautions

No effects or complications reported

If chest pain, palpitations, sweating, diarrhea develop during therapy, discontinue drug

If chest pain, palpitations, sweating, and/or diarrhea develop during therapy, discontinue drug

Tablet, as sodium: 2 mg, 4 mg, 6 mg